ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Testis expressed 19 is a novel cancer-testis antigen expressed in bladder cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Integrating bulk and single-cell RNA sequencing analysis to reveal characterization of mechanical stimulus-related genes and prognostic signatures in breast cancer.Breast cancer research : BCR · 2025Article
- Transcription Factor FOXA1 Facilitates Glycolysis and Proliferation of Lung Adenocarcinoma via Activation of TEX19.Molecular biotechnology · 2024Article
- TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination.Cancer cell international · 2024Article
- Article
- In silico modeling of the interaction between TEX19 and LIRE1, and analysis of TEX19 gene missense SNPs.Molecular genetics & genomic medicine · 2021Article
- Prediction of relapse in stage I testicular germ cell tumor patients on surveillance: investigation of biomarkers.BMC cancer · 2020Article
- Experimental study of the difference in deformation between normal and pathological, renal and bladder, cells induced by acoustic radiation force.European biophysics journal : EBJ · 2020Article
- TEX9 and eIF3b functionally synergize to promote the progression of esophageal squamous cell carcinoma.BMC cancer · 2019Article
- Meiotic gene activation in somatic and germ cell tumours.Andrology · 2019Review
- miRNA-mRNA Associated With Survival in Endometrial Cancer.Frontiers in genetics · 2019Article
- Genome-wide identification of cancer/testis genes and their association with prognosis in a pan-cancer analysis.Oncotarget · 2017Article
- Human germ/stem cell-specific gene TEX19 influences cancer cell proliferation and cancer prognosis.Molecular cancer · 2017Article
- Harnessing antitumor immunity: Employment of tumor recall antigens to optimize the inflammatory response to cancer.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer exhibits high mortality as a result of limited therapeutic options and a high recurrence rate. Accordingly, novel treatments such as immunotherapy have emerged as promising therapeutic modalities to prolong overall patient survival and effect a disease cure, which has renewed enthusiasm for the identification of tumor-specific target antigens. Cancer-testis (CT) antigens are recognized as ideal targets for immunotherapy because of their expression features and high immunogenicity profiles. Here, we investigate the expression pattern of a novel CT antigen, testis-expressed 19 (TEX19), in patients with bladder carcinoma and among multiple human tissues. Six bladder cancer cell lines (T24, UM-UC-3, J82, 5637, SW780, and RT4) were also analyzed for TEX19 expression. Our results reveal that TEX19 expression in normal tissue is restricted to human testis. In addition, TEX19 mRNA expression was detected in 60 % (24/40) bladder cancer samples, whereas 58.20 % (110/189) were positive for TEXT19 protein expression. Compared to low-grade tumors, TEX19 exhibited increased expression in high-grade tumors, from 53.69 to 77.14 %, respectively (P = 0.011). TEX19 was also expressed in all six bladder cancer cell lines. Together, our findings suggest that TEX19 represents a novel CT gene and might play a role in the progression of bladder cancer and that this gene therefore provides a potential target for immunotherapy treatment strategies against bladder cancer.
Indexed as
Identifiers
26695143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.